SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is experiencing significant buzz following FDA approval for YARTEMLEA, its groundbreaking treatment for TA-TMA, which also includes pediatric use. The community is buzzing with excitement over its "first and only" approved status, anticipating a substantial re-rating and potential short squeeze, with many long-term holders eyeing significant upside and a possible buyout by NVO. Despite some discussions around potential profit-taking, a strong sense of long-term value and market opportunity prevails among investors.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its dedicated community actively champions a return to "OG memes" and consistent building within the crypto space. Enthusiasts express strong conviction, highlighting the project's perceived undervaluation and its mission to onboard a million users, fostering a collective bullish sentiment through daily engagement.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, a significant milestone for direct-to-device cellular broadband. While the news sparked initial excitement, it also led to some "sell the news" profit-taking, fueling a dynamic debate between long-term investors focused on the technology's massive potential and those anticipating short-term volatility. The community is actively discussing the company's future catalysts, viewing current dips as accumulation opportunities amidst projected billions in future revenue.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as a high-performance Layer 1 network, boasting over 11 million transactions per second and a compliance-first architecture essential for institutional adoption. The recent live integration with Bridge, a Stripe company, enables seamless fiat on/off-ramps for USD and EUR, positioning KTA as an undervalued solution for global financial plumbing and cross-chain routing.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending amid strong community buzz, driven by discussions surrounding its notably low public float and the potential for a short squeeze following recent significant market activity. Many are highlighting that a substantial portion of shares are locked up for months, suggesting minimal dilution risk and drawing comparisons to other volatile low-float runners within the active Robotics/AI sector. Traders are actively debating market manipulation narratives alongside calls to hold for further upward momentum, especially as attention focuses on warrant exercisability in the coming weeks.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is seeing significant buzz driven by recent regulatory tailwinds and concrete progress on its multi-year strategic overhaul, including its Banamex divestiture. This momentum has led to new highs, with many investors anticipating further upside within a strengthening financial sector, though community sentiment also reflects caution about potential overbought conditions.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is trending sharply higher following significant insider buying, prominently featuring Apple CEO Tim Cook's nearly $3 million share purchase, seen by many as a strong vote of confidence. This has ignited community speculation about a potential market bottom and short squeeze after recent declines, though some remain cautious, pointing to ongoing concerns about challenging sales in China and competitive pressures.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to groundbreaking preliminary data from its FLAMINGO-01 trial, showing an impressive approximately 80% reduction in breast cancer recurrence rates, a development the community views as a significant de-risking event for the immunotherapy. This positive clinical update, coupled with an exceptionally high cost-to-borrow rate and a very low share float, is fueling intense investor speculation about an imminent short squeeze and potential strategic partnerships, as insiders continue to demonstrate strong conviction through share accumulation.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending significantly due to an announced acquisition by Sanofi for $15.50 per share, reflecting an approximate $2.2 billion total equity value, aimed at bolstering Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine and shingles candidate. While many long-term investors are celebrating the substantial gain, the community is actively discussing dissatisfaction with the acquisition price, with many believing the company was undervalued and hoping for potential competing bids.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following recent FDA approval of AQVESME for anemia in adults with alpha- or beta-thalassemia, marking it as the only approved therapy for this rare blood disorder. The community is expressing significant optimism, anticipating upward movement as this decision broadens the company's therapeutic offerings. This development is driving conversations around the stock's potential within the rare disease sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Whitehawk Therapeutics (NASDAQ:WHWK) Now Covered by Jones Trading

Jones Trading started coverage on Whitehawk Therapeutics in a research note on Monday. They issued a "buy" rating and a $7.00 price objective on the stock...

Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer

Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer PR Newswire MORRISTOWN, N.J., Dec. 1, 2025...

Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire...

Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London

Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London PR Newswire MORRISTOWN...

What is HC Wainwright's Estimate for WHWK FY2025 Earnings?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Whitehawk Therapeutics in a note issued to investors on...

Whitehawk Therapeutics (NASDAQ:WHWK) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus...

Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights PR Newswire...

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC Whitehawk Therapeutics Presents Real-World...

Tempus AI Fuels Growth Through Strategic Biotech Collaborations

TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.

Healthtech company Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK) on Thursday, aimed at developing the latter’s cancer treatment pipeline.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tempus.com/news/pr/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research/">deal</a>, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including a de-identified multimodal database, to support its clinical trial designs. A de-identified multimodal database is a collection of diverse datasets, such as medical images, clinical notes, and genetic information, from which all personally identifiable information or protected health information has been removed. It is expected that Tempus’ dataset will help Whitehawk focus on the right patient population.Whitehawk’s antibody drug conjugate portfolio includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers. The collaboration is aimed at advancing research centered on these candidates.“By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline,” said Whitehawk CEO Dave Lennon.<a href="https://stocktwits.com/symbol/WHWK">Whitehawk shares</a> soared 23% on Thursday afternoon at the time of writing, while <a href="https://stocktwits.com/symbol/TEM">Tempus shares</a> dropped about 0.5%.On Stocktwits, retail sentiment around WHWK jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:590/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_26_39_PM_png_87d1a96f13.webp" alt="WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="590" height="61"><figcaption>WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>Retail sentiment around TEM, however, stayed within the ‘bearish’ territory, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:591/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_29_47_PM_png_cc45006531.webp" alt="TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="591" height="61"><figcaption>TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user hopes WHWK rallies into the $4 to $5 range.<stembedurl>https://stocktwits.com/cjstocksup/message/632578934</stembedurl>Another sounded optimistic for TEM stock, citing its relationships with big pharma and strong backlog.<stembedurl>https://stocktwits.com/TICKERTUTOR/message/632569480</stembedurl>WHWK stock has dropped 18% this year, while TEM shares rose 171% during the period.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-rises-after-launch-of-generic-cholestrol-lowering-drug-by-canadian-unit/ch6p4DqR3nu">Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Whitehawk Therapeutics Stock Rallies 25% On Tempus AI Collaboration Deal: Retail Hopes For A Rally Toward $5 Mark

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.

Equity

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.


Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.55	--	--	N/A
Q3 '25	-$0.51	-$0.26	49.02%	BEAT
Q2 '25	$0.82	-$0.76	-192.12%	MISSED
Q1 '25	--	$1.83	--	N/A

WHWK
Whitehawk Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest WHWK News

WHWKWhitehawk Therapeutics Inc.